The U.S. breast cancer screening market is advancing with cutting-edge breast imaging technologies like 3D mammography (digital breast tomosynthesis) and optoacoustic ultrasound. A Yale School of Medicine study analyzing over 272,000 screenings over 13 years found 3D mammograms detect breast cancer earlier than 2D mammography, reducing advanced-stage diagnoses from 44% to 33%. Meanwhile, optoacoustic ultrasound combines laser-induced imaging with traditional ultrasound, improving accuracy in distinguishing benign vs. malignant lesions. These breast cancer detection advancements enhance early diagnosis, boosting survival rates and treatment success.
The U.S. breast cancer screening market is expanding with advanced imaging technologies, as digital mammography now makes up 90% of procedures. Digital breast tomosynthesis (DBT) is gaining traction, detecting 2.1 more cancers per 1,000 screenings than 2D mammography. Rising breast cancer cases and specialized diagnostic centers are fueling growth. BIS Research values the market at $1,556.6 Million in 2024, projecting a 7.05% CAGR to $2,342.2 Million by 2030.
Segmentation 1: based on Technology
• Conventional 2D Mammography
• Digital Breast Tomosynthesis
• Contrast-Enhanced Digital Mammography
• Ultrasound
• MRI Coils
• Others
US Breast Cancer Screening and Diagnostic Market Dynamics: Drivers, Challenges, Opportunities
The rising prevalence of breast cancer is accelerating demand for early detection technologies. With over 300,000 new cases and 3.5 million existing cases reported by the American Cancer Society (2024), healthcare providers are investing in mammography, MRI, and ultrasound to enhance accuracy and patient outcomes.
A shortage of imaging specialists threatens the adoption of advanced breast cancer imaging. The AAMC projects a radiology workforce gap of 10,300–35,600 by 2034, worsened by burnout and an aging workforce, highlighting the urgent need for more radiologists.
Multi-modality imaging is transforming breast cancer diagnostics by integrating mammography, ultrasound, and tomosynthesis for higher accuracy and early detection. As technology advances, adoption of multi-modality systems will further improve diagnostic precision and treatment outcomes.
According to Swati Sood, Principal Analyst at BIS Research, the U.S. breast cancer screening market is growing due to digital breast tomosynthesis (DBT) and enhanced MRI, improving early detection in dense breast tissue. While rising cases drive demand, radiology shortages and personalized treatment needs remain challenges. Expanding access to advanced screening will enhance patient outcomes and sustain market growth.
Explore BIS Research’s tailored Go-to-Market Strategy that help businesses explore and enter emerging markets, promising professional guidance to unlock new opportunities.
